Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) – Market, Industry, Trends, Technologies and Prospects 2015-2025

世界のトップ30医薬品製造受託機関(CMO)

◆タイトル:Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) – Market, Industry, Trends, Technologies and Prospects 2015-2025
◆商品コード:VGAIN5100108
◆調査・発行会社:visiongain
◆発行日:2015年9月
◆ページ数:327
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界のトップ30医薬品製造受託機関(CMO)"について調査・分析し、レポートサマリー、市場の促進要因、抑制要因、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、専門家の見解、結論などの情報をお届けいたします。

Contracted drug production – stay ahead now by exploring leading companies’ prospects
How are pharma contract manufacturing organisations (CMOs) performing? Visiongain’s updated report shows you their prospects to 2025. You discover that outsourcing industry’s results, trends, opportunities and potentials, also with predicted revenues and profits.

Our study analyses 30 top CMOs. There you see how revenues from drug production services can increase. You explore trends, technologies and opportunities shaping that industry. Discover that market’s potential, benefiting your reputation for commercial insight.

That way you find analysis on established and emerging companies across the world. Read on, please, to scan the leading companies and see revenue prediction for their industry.

Forecasts and other data to help you stay ahead, benefiting your influence
In our new study you find analytical profiles of 30 top contractors, and analyses of their overall industry. You discover historical data, market and sales shares, growth rates and revenue forecasts. Also explore qualitative analyses, business outlooks and developments.

Our study gives you 185 tables, 111 charts and three interviews with companies.

That investigation also shows you prospects for these outsourced production segments at world level, including their overall revenue forecasts to 2025:
• Active pharmaceutical ingredients (API) production
• Finished dosage formulations (FDF) manufacturing.

Pharma Leader Series Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, Industry, Trends, Technologies and Prospects 2015-2025

In particular, biologics and biosimilars hold promise. New therapies – including antibody-drug conjugates, high potency APIs and regenerative medicines – increasingly interest CMOs and clients.

Discover, then, what the future holds. The following sections highlight what our research and analyses give you, to benefit planning, proposals and presentations.

Company profiles – explore commercial activities, results, competition and prospects
Our report analyses 30 leading companies. The content of each profile differs, depending on the organisation. In general, though, a profile gives you the following information:
• Overview of the company’s contract manufacturing services and operations
• Analysis of recent financial performance – annual revenue for CMO services, including some data on operating profit and margins
• Assessment of developments – activities, acquisitions, production capacity, deals, new service offerings and collaborations
• SWOT analysis – a firm’s strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2015 onwards
• Forecasting of pharmaceutical manufacturing revenue to 2025 (for 26 firms), as well as projected operating profit and margin for some companies.

Pharmaceutical developers, producers and marketers will increasingly use CMOs. With our study you discover what that industry’s participants offer – along with their trends and revenue potentials – helping you stay ahead in knowledge and benefit your authority.

Pharma Leader Series Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, Industry, Trends, Technologies and Prospects 2015-2025

European contract manufacturing organisations
Our study gives you discussions, financial analyses and commercial outlooks for 14 European CMOs, including these firms:
• Lonza
• Evonik Degussa
• Royal DSM
• Boehringer Ingelheim
• Fareva
• Famar
• Vetter Pharma.

Discover what the future holds for those pharma service providers, including revenue outlooks to 2025. What profitability and other achievements are possible?

CMOs based in the US and Japan
Our report also shows you developments and business outlooks for seven other international drug production contractors:
• Catalent Pharma Solutions
• Patheon
• Baxter BioPharma Solutions
• AbbVie Contract Manufacturing
• Pfizer CentreSource
• Daito Pharmaceutical
• Nipro Corporation.

Our work reveals where sales growth can occur. Many opportunities remain, with high, expanding revenues forecasted from 2015. You discover where prospects for sales expansion exist, seeing what is possible for that business and its leading competitors.

Developed-market API specialists
You also discover outlooks for three top producers of active pharmaceutical ingredients:
• Teva API
• Esteve Química
• Euticals.

Our report shows commercial potentials of that industry. You see possibilities for advancing medical technology and raising business performance, with better serving of clients.

India and China – analysis of pharma manufacturing service providers
Our work assesses six Indian and Chinese companies. You discover activities and prospects of these firms:
• Dr. Reddy’s Laboratories
• Aurobindo Pharma
• Divis Laboratories
• Shandong Xinhua Pharmaceutical
• Zhejiang Hisun Pharmaceutical
• Zhejiang Huahai Pharmaceuticals.

That way you find sales data and underlying trends, exploring what the present and future hold.

Predictions for the worldwide pharma CMO market and submarkets
Our report also forecasts revenues to 2025 for the world contract manufacturing industry and its main segments: APIs and FDFs.

That work predicts high sales growth from 2015 to 2025. Revenues can reach $80.5bn in 2019, with further expansion possible. We predict large companies and specialty healthcare firms will develop and prosper. She why, how and where, finding commercial potentials.

You also discover interviews with authorities in these three companies, hearing how firms think and view prospects for outsourced drug production:
• Corden Pharma
• Siegfried
• PREMAS Biotech.

With our study you explore opportunities and sales predictions for outsourced production of medicines. You investigate established and rising companies, finding trends, outlooks and revenue potentials. See what is possible.

Ways Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) – Market, Industry, Trends, Technologies and Prospects 2015-2025 helps your work
In particular, our new investigation benefits your research, planning and decisions through the following analyses:
• Revenues to 2025 for the world pharma contract manufacturing organisations (CMO) market – discover that industry’s prospects overall and by submarket, finding promising segments for investments, developments and revenue growth
• Profiles of 30 leading companies there – assess services, strategies, sales results and outlooks, gaining revenue forecasts to 2025 for 26 of the firms, also with some profitability predictions
• Interviews with three companies in the CMO industry – explore strategies, debates and opinions, helping you stay ahead in knowledge
• Competition and opportunities – see what affects that industry, exploring what shapes its future, esp. prospects for sustaining and developing business
• Analysis of what stimulates and restrains that industry and market – assess challenges and strengths, helping you compete and succeed.

That report, by visiongain’s in-house analysts in the UK, gives analysis with the purpose of saving you effort and time. You gain data and discussions leading companies depend on.

【レポートの目次】

1. Report Overview
1.1 Leading Contract Manufacturing Organisations (CMOs) Overview
1.2 Benefits of This Report
1.3 How This Report Delivers Information
1.4 Main Questions This Report Answers
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Related Reports
1.9 About Visiongain

2. Introduction to Pharmaceutical Contract Manufacturing, 2015
2.1 What Services Do Contract Manufacturers Offer?
2.1.1 Why Do Firms Outsource Manufacturing?
2.1.2 What Is Driving Demand for Contract Manufacturing Services?
2.2 The Pharmaceutical Contract Manufacturing Market, 2014
2.2.1 Where is Supply and Demand Highest for Contract Manufacturing Services?
2.3 Outlook for the Pharmaceutical Contract Manufacturing Market 2015-2025
2.4 Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing, 2015-2025
2.4.1 Pharmaceutical Contract Manufacturing: Market Drivers 2015-2025
2.4.2 Pharmaceutical Contract Manufacturing: Market Restraints 2015-2025
2.5 Who Are the Leading Pharmaceutical Contract Manufacturers in 2014?

3. Leading CMOs in North America
3.1 Catalent Pharma Solutions- One of the World’s Leading CMO
3.1.1 Catalent: Manufacturing Services and Capabilities
3.1.2 Divisional Segmentation – Breaking Down Catalent’s Service
3.1.3 Catalent Pharma’s Revenue Growth, 2010-2014
3.1.4 Sustained Growth in Oral Products: Catalent Pharma’s Divisional Performance, 2010-2014
3.1.5 Catalent Is Expanding its Oral Technologies Division
3.1.6 Quadrupling Biopharmaceutical Manufacturing Capacity
3.1.7 Expansion of Packaging Services in Asia-Pacific and Europe: 2015
3.1.8 Adding New Early-Stage Development Services
3.1.9 Expansion in Japan – Growth Prospects for Catalent
3.1.10 New Business Contracts 2014-2015
3.1.11 Catalent New Products Launch
3.1.12 Catalent: Opportunities for Growth 2015-2025
3.1.13 Catalent: Mild Growth in Revenue, 2015-2025
3.2 Patheon – One of The Top 3 CMOs
3.2.1 Patheon – Global leader in Pharmaceutical Development Services
3.2.2 Contract Manufacturing Services at Patheon
3.2.3 Steady Revenue Growth 2010-2014
3.2.4 DPx Holdings: Developments
3.2.5 Adding New Formulations and Formulation Development Services
3.2.6 Reassessing Manufacturing Capacity
3.2.7 Expanding Services Through Acquisition, 2015
3.2.8 Patheon: SWOT Analysis 2015-2025
3.2.9 Patheon: Contract Manufacturing Revenue Forecast 2015-2025
3.3 Baxter BioPharma Solutions
3.3.1 Baxter BioPharma is the Global Leader in Sterile Fill and Finish
3.3.2 Historic Revenue Performance 2010-2014
3.3.3 Baxter BioPharma SWOT Analysis 2015-2025
3.3.4 Baxter BioPharma Revenue Forecast 2015-2025
3.4 AbbVie Contract Manufacturing
3.4.1 AbbVie Offers Full-Service Contract Manufacturing
3.4.2 Expanding and Adding New Services: 2013-2014
3.4.3 AbbVie Contract Manufacturing: Revenue 2011-2014
3.4.4 Biologics and HPAPIs Are an Opportunity for Growth 2015-2025
3.4.5 AbbVie Contract Manufacturing Revenue Forecast 2015-2025
3.5 Pfizer CentreSource
3.5.1 Pfizer CentreSource: Historic Revenue Performance, 2010-2014
3.5.2 Will Pfizer Divest CentreSource?
3.5.3 Outlook for CentreSource: Revenue Forecast 2015-2025

4. Leading European Contract Manufacturing Organisations
4.1 Lonza
4.1.1 Lonza Is a Leader in Biologics Manufacturing
4.1.2 Lonza Contract Manufacturing and Development: 2010-2014
4.1.3 Investing in Advanced Biological Drug Sectors
4.1.4 The Promise of Antibody-Drug Conjugates (ADCs)
4.1.5 The Regenerative Medicine Future in Japan
4.1.6 Lonza: SWOT Analysis 2015-2025
4.1.7 Biologics and Efficiency Savings Will Drive Growth in Revenue and Operating Profit for Lonza 2015-2025
4.2 Evonik Degussa
4.2.1 Investing in API and Drug Delivery Services
4.2.2 Moderate Growth in Pharmaceutical Manufacturing Services, 2010-2014
4.2.3 Evonik Is a HPAPI Specialist
4.2.4 Evonik Continues to Grow Across All Segments
4.2.5 How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
4.2.6 Evonik Degussa: Revenue Forecast 2015-2025
4.3 Royal DSM – The World’s Leading CMO
4.3.1 Amplified Revenue Growth in Pharma Manufacturing 2010-2014
4.3.2 DSM Pharmaceuticals Products: Manufacturing Services 2010-2014
4.3.3 DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
4.3.4 DPx Holdings: A New Pharma Leader
4.3.5 Investing in Biopharma Manufacturing
4.3.6 Expanding API Manufacturing
4.3.7 Generics and Biologics Are an Opportunity for Growth, 2014-2025
4.3.8 DSM Pharmaceuticals Products: Revenue Forecast 2015-2025
4.4 Boehringer Ingelheim Contract Manufacturing
4.4.1 Expanding Biopharmaceuticals Manufacturing Services in China
4.4.2 Production Through to Fill and Finished Biopharmaceuticals
4.4.3 A Track Record of Production for 29 Biopharma Products
4.4.4 Increasing Revenue from Contract Manufacturing, 2010-2014
4.4.5 Pulling Out of Small Molecule API Manufacturing
4.4.6 Expanding through New Services
4.4.7 Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth 2015-2025
4.4.8 Boehringer Ingelheim: Revenue Forecast 2015-2025
4.5 Fareva
4.5.1 Fareva Has 35 Years’ Manufacturing Experience
4.5.2 Revenue Growth through Acquisitions: 2010-2014
4.5.3 Fareva SWOT Analysis: 2015
4.5.4 Fareva Revenue Forecast: 2015-2025
4.6 Aenova Group
4.6.1 Acquisition of Haupt Creates European CMO Giant
4.6.2 Aenova’s Ever Expanding Manufacturing Capacity
4.6.3 Aenova’s Revenue 2010-2014: Organic Growth and Acquisitions
4.6.4 Aenova’s Competitive Position in the Contract Manufacturing Market: SWOT Analysis 2015
4.6.5 Becoming a Leading Contract Manufacturer: Aenova Revenue Forecast 2015-2025
4.7 Famar
4.7.1 Famar Is an Expert in Lyophilisation
4.7.2 Sustained Growth in Famar’s Revenue: 2010-2014
4.7.3 Expanding European Operations
4.7.4 Further Site Acquisitions Are an Opportunity for Growth 2015-2025
4.7.5 How Will Famar Perform 2015-2025?
4.8 Vetter Pharmaceutical
4.8.1 Vetter is an Injectable Manufacturing Specialist
4.8.2 Rapidly Growing Revenue in the US and Germany: 2010-2014
4.8.3 Services, Collaborations and Differentiating Factors
4.8.4 Expanding Services in US and Asia
4.8.5 Biologics Are an Opportunity for Growth for Vetter 2015-2025
4.8.6 Vetter Outlook: Revenue Forecast 2015-2025
4.9 Almac Group
4.9.1 Almac’s Manufacturing Services
4.9.2 Almac Outpaces the Market: 2011-2014
4.9.3 Almac Adding Capacity Globally
4.9.4 New Services Added 2012-2015
4.9.5 Almac Group: Contract Manufacturing Market Outlook 2015-2025
4.9.6 How Will Almac Group Perform 2015-2025?
4.10 Delpharm
4.10.1 Finished Dosage Form Manufacturing for Developed Markets
4.10.2 Delpharm: Rapid Revenue Growth Via Acquisitions, 2010-2014
4.10.3 Delpharm: Outlook and Prospects for Growth 2015-2025
4.10.4 Generics Will Drive Revenue Growth for Delpharm 2015-2025
4.11 Siegfried
4.11.1 Siegfried’s Acquisitions, 2010-2014
4.11.2 Expanding Siegfried’s Manufacturing Footprint Globally
4.11.3 Expanding High Potency API Capabilities
4.11.4 Siegfried: Financial Performance 2010-2014
4.11.5 Siegfried’s Characteristics within the Contract Manufacturing Market: SWOT Analysis 2015
4.11.6 Continued Revenue Growth for Siegfried 2015-2025
4.12 Corden Pharmaceutical
4.12.1 CordenPharma Service Division
4.12.2 CordenPharma Emerging in the API Market
4.12.3 Investments in Highly Potent Capabilities
4.12.4 CordenPharma: SWOT Analysis 2015-2025
4.13 Recipharm
4.13.1 Contract Development and Manufacturing Services
4.13.2 Recipharm: Financial Performance 2010-2014
4.13.3 Recipharm Invests in Facility Expansion
4.13.4 Recipharm Growing in Development & Technology Market through Acquisitions
4.13.5 Recipharm: Opportunities for Growth 2015-2025
4.13.6 Outlook for Recipharm: Revenue Forecast 2015-2025
4.14 Aesica Pharmaceuticals
4.14.1 Aesica Manufactures APIs and Finished Dosage Forms
4.14.2 Acquisitions Drive Revenue Growth but Operational Margins Have Declined, 2010-2014
4.14.3 Partnering with Academia for Innovative Solutions
4.14.4 Growth through Acquisitions and Internal Expansion
4.14.5 Aesica: Opportunities for Expansion 2015-2025
4.14.6 Forecast Aesica Financial Performance, 2015-2025

5. Leading Japanese Pharma Contract Manufacturing Organisations
5.1 Nipro Corporation: Japan’s Leading CMO
5.1.1 Nipro Pharmaceutical Contract Manufacturing Capabilities
5.1.2 Nipro: Decline in Revenue But Increasing Operating Profits 2010-2014
5.1.3 Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis 2015
5.1.4 Nipro Revenue and Profitability Forecast 2015-2025
5.2 Daito Pharmaceutical
5.2.1 Daito Has a Portfolio of More than 30 APIs
5.2.2 Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2010-2014
5.2.3 Daito Is Well-Placed for Asian Market Growth – SWOT Analysis 2015-2025
5.2.4 Sustained Growth in Revenue and Operating Profit for Daito, 2015-2025

6. Leading Developed-Market API Specialists
6.1 Teva API
6.1.1 API Manufacturing Services
6.1.2 Teva API: Financial Performance 2010-2014
6.1.3 Building a Footprint in Mexico, India and China
6.1.4 Teva API: SWOT Analysis 2015
6.1.5 Outlook for Teva API: Revenue Forecast 2015-2025
6.2 Esteve Química
6.2.1 Esteve Química Manufactures APIs for Developed and Emerging Markets
6.2.2 Expanding in The US, 2015
6.2.3 Esteve Química: SWOT Analysis 2015-2025
6.3 Euticals
6.3.1 Euticals Manufactures More than 200 APIs
6.3.2 Acquisitions Drive Growth 2010-2014
6.3.3 Adding Capacity for Finished Dosage Forms
6.3.4 Asian Expansion Is an Opportunity for Growth 2015-2025
6.3.5 Euticals: Revenue Forecast 2015-2025

7. Leading Chinese Pharmaceutical Contract Manufacturers
7.1 Zhejiang Hisun Pharmaceutical
7.1.1 API Manufacturing for Markets Worldwide
7.1.2 Zhejiang Hisun’s Rapid Growth in API Revenue Grows, 2010-2014
7.1.3 Moving Into International Drug Marketing
7.1.4 Zhejiang Hisun: Opportunities for Growth 2015-2025
7.1.5 Zhejiang Hisun: Strong API Revenue Growth 2015-2025
7.2 Zhejiang Huahai Pharmaceuticals
7.2.1 Zhejiang Huahai Is a Market Leader Within The Antihypertensive API Market
7.2.2 Zhejiang Huahai: Contract Manufacturing Performance 2010-2014
7.2.3 Expanding in the US Generic Drugs Market
7.2.4 Zhejiang Huahai: SWOT Analysis, 2015
7.2.5 Zhejiang Huahai: Revenue Forecast, 2015-2025
7.3 Shandong Xinhua Pharmaceutical
7.3.1 Experience in APIs and Finished Dosage Forms
7.3.2 Shandong Xinhua: Strong Revenue Growth 2010-2014
7.3.3 Growing through Joint Ventures
7.3.4 Looking to Expand in the US and EU 2015-2025
7.3.5 Shandong Xinhua Pharmaceutical: Revenue Forecast 2015-2025

8. Leading Indian Pharmaceutical Contract Manufacturers
8.1 Aurobindo Pharma
8.1.1 API Manufacturing Services
8.1.2 Aurobindo Pharma: Steady Revenue Growth 2010-2014
8.1.3 Aurobindo Expanding Outside of Antibacterials
8.1.4 Aurobindo: Opportunities for Expansion 2015-2025
8.1.5 How Will Aurobindo’s Contract Manufacturing Division Perform 2015-2025?
8.2 Divis Laboratories
8.2.1 Divis Laboratories and the Contract Manufacturing Industry
8.2.2 Divis Laboratories: A Rapidly Growing CMO, 2010-2014
8.2.3 Divis Laboratories: API Manufacturing Outlook 2015-2025
8.2.4 Divis Laboratories: API Manufacturing Revenue Forecast, 2015-2025
8.3 Dr. Reddy’s Laboratories
8.3.1 API and FDF Manufacturing Services
8.3.2 Dr. Reddy’s PSAI: Strong Revenue Growth 2010-2014
8.3.3 Advancing in Complex Drug Manufacturing
8.3.4 Expanding in the European Manufacturing Market
8.3.5 Dr. Reddy’s PSAI Division: Revenue Forecast 2015-2025

9. Research Interviews from Our Industry Survey
9.1 Dr Michael Quirmbach, Vice President, Global Sales & Marketing, CPI, Corden Pharma
9.2 Mrs Marianne Spaene, Executive Vice President, Global Head Business Development, Sales and Marketing, Siegfried
9.3 Dr Prabuddha Kundu, Cofounder & Executive Director, PREMAS Biotech

10. Conclusions of the Study
10.1 What Has Driven Growth for CMO Market Leaders in Recent Years?
10.2 Strategies for Growth: Prospects For Leading CMOs, 2015-2025
10.3 High Demand for Biopharmaceutical Manufacturing Services
10.4 Investing in Novel Technologies
10.5 Outlook for API Manufacturers

Table 1.1 Leading Pharmaceutical Contract Manufacturing Organisations: Rank, Revenue ($m), Market Share (%), 2014
Table 1.2 Foreign Currency Exchange Rates Used: 2014 Average Exchange Rate to $US
Table 2.1 Benefits and Drawbacks to Outsourcing Pharmaceutical Manufacturing, 2015
Table 2.2 Contract Manufacturing Market Total Revenue: Total Revenue ($bn), Annual Growth (%), 2012-2014
Table 2.3 Contract Manufacturing Market by Service: Market Size ($bn), Market Share (%), 2013
Table 2.4 Contract Manufacturing Market by Leading Country: Market Size ($bn), Market Share (%), 2013
Table 2.5 Contract Manufacturing Market by Service: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019 and 2025
Table 2.6 Leading Pharmaceutical Contract Manufacturing Organisations: Rank, Revenue ($m), Market Share (%), 2014
Table 3.1 Catalent Details, 2015
Table 3.2 Catalent Facility Details, 2015
Table 3.3 Catalent Financial Performance: Revenue ($m), 2010-2014
Table 3.4 Catalent Financial Performance by Product Type: Revenue ($m), Revenue Share (%), 2014
Table 3.5 Catalent Financial Performance by Division: Revenue ($m), Annual Growth Rate (%), Revenue Share (%), CAGR (%), 2010-2014
Table 3.6 Catalent New Products Launch: New Products, Annual Growth (%), CAGR (%), 2012-2014
Table 3.7 Catalent Pharma SWOT Analysis, 2015
Table 3.8 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2019
Table 3.9 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2019-2025
Table 3.10 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2019
Table 3.11 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2019-2025
Table 3.12 Patheon Details, 2015
Table 3.13 Patheon Manufacturing Facilities, 2014
Table 3.14 Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2010-2014
Table 3.15 Patheon: SWOT Analysis, 2015
Table 3.16 Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 3.17 Baxter BioPharma Solutions Details, 2015
Table 3.18 Baxter BioPharma Solutions: Facilities and Services Offered, 2014
Table 3.19 Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
Table 3.20 Baxter BioPharma Solutions SWOT Analysis, 2015
Table 3.21 Forecast Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 3.22 AbbVie Contract Manufacturing: Details, 2015
Table 3.23 AbbVie Contract Manufacturing Facility Capabilities, 2014
Table 3.24 AbbVie Pharmaceutical Manufacturing: Revenue ($m) Annual Growth Rate (%), CAGR (%), 2011-2014
Table 3.25 AbbVie Contract Manufacturing SWOT Analysis, 2015
Table 3.26 Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 3.27 Pfizer CentreSource Details, 2015
Table 3.28 Pfizer CentreSource: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 3.29 Pfizer CentreSource SWOT Analysis, 2015
Table 3.30 Forecast Pfizer CentreSource Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 4.1 Lonza Details, 2015
Table 4.2 Selected Lonza Pharmaceutical and Biotech Manufacturing and Development Agreements, 2010-2015
Table 4.3 Lonza Pharma & Biotech Department: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2010-2014
Table 4.4 ADCs Approved and in Late Stage Clinical Development, 2014
Table 4.5 Lonza SWOT Analysis, 2015
Table 4.6 Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2014-2019
Table 4.7 Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2019-2025
Table 4.8 Evonik Degussa Details, 2015
Table 4.9 Evonik Health and Nutrition: R&D and Production Sites by Region, 2014
Table 4.10 Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
Table 4.11 Evonik Pharmaceutical Manufacturing: SWOT Analysis, 2015
Table 4.12 Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 4.13 Royal DSM Details, 2015
Table 4.14 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
Table 4.15 DSM Pharmaceutical Products (DPP)/DPx Holdings Division: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
Table 4.16 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
Table 4.17 DSM Pharmaceutical Manufacturing: SWOT Analysis, 2015
Table 4.18 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2019
Table 4.19 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2019-2025
Table 4.20 Boehringer Ingelheim Biopharmaceuticals Details, 2015
Table 4.21 Boehringer Ingelheim Total Pharmaceutical Manufacturing Capacity: Reactor Size and Number of Units by CMO Service, 2014
Table 4.22 Products Developed by Boehringer Ingelheim Biopharmaceuticals, 1983-2014
Table 4.23 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
Table 4.24 Boehringer Ingelheim: SWOT Analysis, 2015
Table 4.25 Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 4.26 Fareva Details, 2015
Table 4.27 Fareva Manufacturing Facilities, 2014
Table 4.28 Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 4.29 Fareva: SWOT Analysis, 2015
Table 4.30 Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 4.31 Aenova Group Details, 2015
Table 4.32 Aenova Group Manufacturing Capacity by Dosage Form, 2015
Table 4.33 Aenova Group Manufacturing Facility Details, 2015
Table 4.34 Aenova Group Pharmaceutical Manufacturing: Revenue ($m), 2011-2014
Table 4.35 Aenova Group SWOT Analysis, 2015
Table 4.36 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2014-2019
Table 4.37 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2019-2025
Table 4.38 Famar Details, 2015
Table 4.39 Famar Pharmaceutical Manufacturing Facilities, 2014
Table 4.40 Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 4.41 Famar: SWOT Analysis, 2015
Table 4.42 Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 4.43 Vetter Details, 2015
Table 4.44 Vetter Pharmaceutical Manufacturing Facilities, 2014
Table 4.45 Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 4.46 Vetter: SWOT Analysis, 2015
Table 4.47 Forecast Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 4.48 Almac Details, 2015
Table 4.49 Almac Pharmaceutical Manufacturing Facilities Details, 2014
Table 4.50 Almac Pharmaceutical Manufacturing: Revenue ($m), 2011-2014
Table 4.51 Almac: SWOT Analysis, 2015
Table 4.52 Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2014-2019
Table 4.53 Forecast Almac Pharmaceuticals: Revenue ($m), 2019-2025
Table 4.54 Delpharm Details, 2015
Table 4.55 Delpharm: Facilities and Services, 2014
Table 4.56 Delpharm: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 4.57 Delpharm: SWOT Analysis, 2015
Table 4.58 Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 4.59 Siegfried Details, 2015
Table 4.60 Siegfried Pharmaceutical Manufacturing Facilities Details, 2015
Table 4.61 Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2010-2014
Table 4.62 Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2010-2014
Table 4.63 Siegfried: SWOT Analysis, 2015
Table 4.64 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2014-2019
Table 4.65 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2019-2025
Table 4.66 CordenPharma Details, 2015
Table 4.67 CordenPharma Facilities and Service Details, 2014
Table 4.68 Corden Pharmaceuticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2014
Table 4.69 Corden Pharmaceuticals SWOT Analysis, 2015
Table 4.70 Recipharm Details, 2015
Table 4.71 Recipharm: Facility Details and Services, 2014
Table 4.72 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2010-2014
Table 4.73 Recipharm Manufacturing Revenue by Client Size: Revenue ($m), Share of Total Revenues (%), 2014
Table 4.74 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), Share of Total Revenues (%), 2014
Table 4.75 Recipharm: SWOT Analysis, 2015
Table 4.76 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2014-2019
Table 4.77 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2019-2025
Table 4.78 Aesica Details, 2015
Table 4.79 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2010-2014
Table 4.80 Aesica SWOT Analysis, 2015
Table 4.81 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2014-2019
Table 4.82 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2019-2025
Table 5.1 Nipro Pharma Details, 2015
Table 5.2 Nipro Pharmaceutical Contract Manufacturing Capabilities: 2009-2014
Table 5.3 Nipro Pharmaceutical Contract Manufacturing: Annual Production Capacity, 2014
Table 5.4 Nipro Pharmaceutical Contract Manufacturing Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2010-2014
Table 5.5 Nipro Pharmaceutical Contract Manufacturing SWOT Analysis, 2015
Table 5.6 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2014-2019
Table 5.7 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2019-2025
Table 5.8 Daito Pharmaceuticals: Details, 2015
Table 5.9 Daito Pharmaceuticals Financial Performance: Revenue ($m), Revenue (¥m), Operating Profit ($m), Operating Profit (¥m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2010-2014
Table 5.10 Daito Pharmaceuticals SWOT Analysis, 2015
Table 5.11 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2014-2019
Table 5.12 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2019-2025
Table 6.1 Teva API Details, 2015
Table 6.2 Teva API: Site Acquisitions, 1980- 2011
Table 6.3 Teva API: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 6.4 Teva API SWOT Analysis, 2015
Table 6.5 Forecast Teva API Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 6.6 Esteve Química Details, 2015
Table 6.7 Esteve Química SWOT Analysis, 2015
Table 6.8 Euticals Details, 2015
Table 6.9 Euticals Facility Details: Production Capacity (m3) and Key Products, 2015
Table 6.10 Euticals Cumulative Regulatory Filings by Region/Country: Filings, Share of Total (%), 2014
Table 6.11 Euticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 6.12 Euticals Revenue by Product Class: Revenue ($m), Share of Total (%), 2014
Table 6.13 Euticals Revenue by Region: Revenue ($m), Share of Total (%), 2014
Table 6.14 Euticals SWOT Analysis, 2015
Table 6.15 Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 7.1 Zhejiang Hisun Pharmaceuticals Details, 2015
Table 7.2 Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 7.3 Zhejiang Hisun Manufacturing: SWOT Analysis, 2015
Table 7.4 Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 7.5 Zhejiang Huahai Pharmaceuticals Details, 2015
Table 7.6 Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 7.7 Zhejiang Huahai Contract Manufacturing: SWOT Analysis, 2015
Table 7.8 Forecast Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 7.9 Shandong Xinhua Pharmaceuticals Details, 2015
Table 7.10 Shandong Xinhua Pharmaceutical Production Capacity by Dosage Form, 2015
Table 7.11 Shandong Xinhua: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 7.12 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 2014
Table 7.13 Shandong Xinhua Manufacturing: SWOT Analysis, 2015
Table 7.14 Forecast Shandong Xinhua Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 8.1 Aurobindo Pharma Details, 2015
Table 8.2 Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 8.3 Aurobindo Contract Manufacturing Revenue by API Class: Revenue ($m), Revenue Share (%), 2014
Table 8.4 Aurobindo Contract Manufacturing: SWOT Analysis, 2015
Table 8.5 Forecast Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 8.6 Divis Laboratories Details, 2015
Table 8.7 Divis Laboratories: Facility Details, Production Capacity and Services, 2015
Table 8.8 Divis Laboratories: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 8.9 Divis Laboratories Revenue Distribution: Revenue ($m), Share of Total (%), 2014
Table 8.10 Divis Laboratories Revenue by Region: Revenue ($m), Share of Total (%), 2014
Table 8.11 Divis Laboratories Contract Manufacturing: SWOT Analysis, 2015
Table 8.12 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m),EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2014-2019
Table 8.13 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2019-2025
Table 8.14 Dr. Reddy’s Laboratories Details, 2015
Table 8.15 Dr. Reddy’s Laboratories Cumulative Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), 1987-2014
Table 8.16 Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 8.17 Dr. Reddy’s Laboratories Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), FY 2014
Table 8.18 Dr. Reddy’s Laboratories: Contract Manufacturing Revenue ($m) by Regional Market and Revenue Share (%), FY 2014
Table 8.19 Dr. Reddy’s Laboratories: SWOT Analysis, 2015
Table 8.20 Forecast Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 10.1 Top Five Developed and Emerging Market CMOs: Grouped Revenues ($bn), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 10.2 CMOs by Absolute Change in Revenue ($m): Annual Revenue ($m), Absolute Change in Revenue ($m), 2010-2014
Table 10.3 Leading CMOs: Combined Annual Revenue ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2014-2025
Table 10.4 Top Five Developed and Emerging Market CMOs: Grouped Revenues ($bn), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 10.5 CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2014-2019
Table 10.6 CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2019-2025

Figure 1.1 Segmentation of Contract Manufacturing Organisations, 2015
Figure 2.1 Selected Services Contracted to CMOs by Developmental Stage, 2015
Figure 2.2 Contract Manufacturing Market Total Revenue: Total Revenue ($bn), 2012-2014
Figure 2.3 Contract Manufacturing Market by Service: Market Share (%), 2013
Figure 2.4 Contract Manufacturing Market by Leading Country: Market Share (%), 2013
Figure 2.5 Contract Manufacturing Market by Service: Market Size ($bn), 2014, 2019 and 2025
Figure 2.6 Pharmaceutical Contract Manufacturing: Drivers and Restraints, 2015-2025
Figure 3.1 Catalent Facilities by Region, 2014
Figure 3.2 Catalent Facilities by Service Offered, 2014
Figure 3.3 Catalent Financial Performance: Revenue ($m), 2010-2014
Figure 3.4 Catalent Financial Performance by Product Type: Revenue Share (%), 2014
Figure 3.5 Catalent Financial Performance by Division: Revenue ($m), 2010-2014
Figure 3.6 Catalent New Products Launch: New products, 2012-2014
Figure 3.7 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), 2014-2019
Figure 3.8 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), 2019-2025
Figure 3.9 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), 2014-2025
Figure 3.10 Patheon Pharmaceutical Development Projects (%) by Phase, 2014
Figure 3.11 Patheon Pharmaceutical Manufacturing Projects by Client Size: Proportion of Total Revenue (%), 2014
Figure 3.12 Patheon Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
Figure 3.13 Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
Figure 3.14 Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2014-2025
Figure 3.15 Baxter BioPharma Manufacturing: Revenue ($m), 2010-2014
Figure 3.16 Forecast Baxter BioPharma Manufacturing: Revenue ($m), 2014-2025
Figure 3.17 AbbVie Pharmaceutical Manufacturing: Revenue ($m)*, 2011-2014
Figure 3.18 Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
Figure 3.19 Pfizer CentreSource: Revenue ($m), 2010-2014
Figure 3.20 Forecast Pfizer CentreSource Manufacturing: Revenue ($m), 2014-2025
Figure 4.1 Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2010-2014
Figure 4.2 Lonza Custom Manufacturing by Regional Market: Revenue Share (%), 2014
Figure 4.3 Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2014-2019
Figure 4.4 Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2019-2025
Figure 4.5 Evonik Health and Nutrition: R&D and Production Sites (%) by Region, 2014
Figure 4.6 Evonik Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
Figure 4.7 Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
Figure 4.8 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
Figure 4.9 Royal DSM Pharmaceutical Manufacturing by Division: Revenue ($m), 2010-2014
Figure 4.10 DSM Pharmaceutical Products (DPP) Division: Revenue ($m), 2010-2014
Figure 4.11 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), 2010-2014
Figure 4.12 Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2014-2025
Figure 4.13 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
Figure 4.14 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
Figure 4.15 Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
Figure 4.16 Fareva Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
Figure 4.17 Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
Figure 4.18 Aenova Group Pharmaceutical Manufacturing: Revenue ($m), 2011-2014
Figure 4.19 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), 2014-2019
Figure 4.20 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), 2019-2025
Figure 4.21 Famar Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
Figure 4.22 Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
Figure 4.23 Vetter Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
Figure 4.24 Forecast Vetter Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
Figure 4.25 Almac Pharmaceutical Manufacturing: Revenue ($m), 2011-2014
Figure 4.26 Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), 2014-2019
Figure 4.27 Forecast Almac Pharmaceuticals: Revenue ($m), 2019-2025
Figure 4.28 Delpharm: Revenue ($m), 2010-2014
Figure 4.29 Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
Figure 4.30 Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2010-2014
Figure 4.31 Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), 2010-2014
Figure 4.32 Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2013
Figure 4.33 Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2014
Figure 4.34 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2014-2019
Figure 4.35 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2019-2025
Figure 4.36 Corden Pharmaceuticals: Revenue ($m), 2012-2014
Figure 4.37 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2010-2014
Figure 4.38 Recipharm Manufacturing Revenue by Client: Share of Total Revenues (%), 2014
Figure 4.39 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), 2014
Figure 4.40 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2014-2019
Figure 4.41 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2019-2025
Figure 4.42 Aesica Pharmaceuticals: Revenue ($m)*, Operating Profit ($m)*, Operating Margin (%), 2010-2014
Figure 4.43 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2014-2019
Figure 4.44 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2019-2025
Figure 5.1 Nipro Pharmaceutical Contract Manufacturing Capabilities: Orally Administered Drugs, Injectables, External Preparations, 2009-2014
Figure 5.2 Nipro Pharmaceuticals Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2010-2014
Figure 5.3 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2014-2019
Figure 5.4 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2019-2025
Figure 5.5 Daito Pharmaceuticals Financial Performance: Revenue (¥m), Operating Profit (¥m), Operating Margin (%), 2010-2014
Figure 5.6 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2014-2019
Figure 5.7 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2019-2025
Figure 6.1 Teva API: Revenue ($m), 2010-2014
Figure 6.2 Forecast Teva API Manufacturing: Revenue ($m), 2014-2025
Figure 6.3 Euticals Cumulative Regulatory Filings by Region/Country: Share of Total (%), 2014
Figure 6.4 Euticals: Revenue ($m), 2010-2014
Figure 6.5 Euticals Revenue by Product Class: Share of Total Revenues (%), 2014
Figure 6.6 Euticals Revenue by Region: Share of Total Revenues (%), 2014
Figure 6.7 Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
Figure 7.1 Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2010-2014
Figure 7.2 Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2014-2025
Figure 7.3 Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2010-2014
Figure 7.4 Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2014-2025
Figure 7.5 Shandong Xinhua: Revenue ($m), 2010-2014
Figure 7.6 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 1H 2014
Figure 7.7 Forecast Shandong Xinhua Manufacturing: Revenue ($m), 2014-2025
Figure 8.1 Aurobindo Contract Manufacturing: Revenue ($m), 2010-2014
Figure 8.2 Aurobindo Contract Manufacturing: Revenue Share (%), 2014
Figure 8.3 Forecast Aurobindo Contract Manufacturing: Revenue ($m), 2014-2025
Figure 8.4 Divis Laboratories Contract Manufacturing: Revenue ($m), EBTDA ($m), EBITDA Margin (%), 2010-2014
Figure 8.5 Divis Laboratories Revenue Distribution: Revenue ($m), 2014
Figure 8.6 Divis Laboratories Revenue by Region: Share of Total (%), 2014
Figure 8.7 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), 2014-2019
Figure 8.8 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), 2019-2025
Figure 8.9 Dr. Reddy’s Laboratories Cumulative Drug Master File (DMF) Applications: Accepted by Region (%), 1987-2014
Figure 8.10 Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), 2010-2014
Figure 8.11 Dr. Reddy’s Laboratories Drug Master File (DMF) Applications: Accepted Applications by Region (%), FY 2014
Figure 8.12 Dr. Reddy’s Laboratories Contract Manufacturing Revenue: Regional Revenue Share (%), FY 2014
Figure 8.13 Forecast Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), 2014-2025
Figure 10.1 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($bn), 2010-2014
Figure 10.2 Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2010-2014
Figure 10.3 Leading CMOs: Combined Annual Revenue ($bn), 2014-2025
Figure 10.4 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($bn), 2014-2025
Figure 10.5 Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2014-2019
Figure 10.6 Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2019-2025

【レポートのキーワード】

医薬品製造受託機関(CMO)、製薬、製造

★調査レポート[世界のトップ30医薬品製造受託機関(CMO)] ( Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) – Market, Industry, Trends, Technologies and Prospects 2015-2025 / VGAIN5100108) 販売に関する免責事項
[世界のトップ30医薬品製造受託機関(CMO)] ( Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) – Market, Industry, Trends, Technologies and Prospects 2015-2025 / VGAIN5100108) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆